key: cord-1003152-as5smzxs
authors: Matsumoto, Toshihiko; Usami, Takashi; Yamamoto, Taisuke; Funada, Daisuke; Murakami, Maki; Okita, Kyoji; Shimane, Takuya
title: Impact of COVID‐19‐related stress on methamphetamine users in Japan
date: 2021-05-10
journal: Psychiatry Clin Neurosci
DOI: 10.1111/pcn.13220
sha: 2e19c59973ba4c0c55b70394adf10d265ab23dd9
doc_id: 1003152
cord_uid: as5smzxs

nan

Studies worldwide have observed that COVID-19 pandemic-related stress (such as the various constraints of everyday life, and anxiety) promotes the use of drugs as a coping behavior. [1] [2] [3] [4] Access to alternative maintenance medication of patients with opioid addiction has been reported to have been restricted, resulting in aggravation of their medical conditions 5 ; perhaps relatedly, opioid-overdose deaths have increased. 6 In Japan, however, the current situation is unknown. We therefore sought to investigate the negative impact of COVID-19 on drug users who take methamphetamine (MAP), which is one of the most abused drugs in Japan.

Biennially, we conduct national surveys of patients with drug-related psychiatric disorders who were admitted to or received outpatient treatment at psychiatric hospitals throughout Japan between September and October of that year. Information is collected via survey forms mailed to each target hospital, where the attending psychiatrist enters clinical information into the form by transcribing medical records and by conducting interviews. Survey items include demographic variables, education, work status, criminal record, presence/absence of problem drinking, duration of therapy, recovery program (group therapy or self-help group) participation status, mainly used drug, and ICD-10 diagnoses. The 2020 survey added two items: COVID-19-related relapse (aggravation of substance abuse due to COVID-19-related stress, which was clinically determined by each attending psychiatrist), and COVID-19-related inhibition of recovery program participation (group therapy and self-help groups having been temporarily suspended as social distance cannot be ensured in such settings). This study was conducted after approval by the ethics committee of the National Center of Neurology and Psychiatry, and it is conformed to the provisions of the Declaration of Helsinki. The attending psychiatrist gave informed consent, and patient anonymity has been preserved.

In the 2020 survey, 1217 (78.1%) of 1558 target hospitals nationwide provided data on 2733 patients with drug-related psychiatric disorders (95.6% of 2859 patients consented this survey); of these, the 1461 patients (1076 men, 385 women) who used MAP as a main drug were the subjects of the present study, and 407 patients (27.9%) had used MAP within the past year while the rest (72.1%) had maintained no use of MAP by continuing treatment.

Of the subjects, the 85 patients (5.8%) were considered to have a COVID-19-related relapse. Table 1 shows the results of a logistic regression analysis conducted by setting COVID-19-related relapse as the The results of this study indicate that, for MAP-dependent patients who recently started their treatment, and therefore, who might not have achieved abstinence yet, the COVID-related barriers to participation in group therapy and self-help groups may increase risk of relapse. Our study also suggests that alcohol use (possibly also to cope with COVID-19-related stress) may increase the relapse risk in male MAP users. Furthermore, a 'stay-athome' lifestyle is speculated to be stressful to promote relapse in those who suffer from attention-deficit/hyperactive disorder (ADHD), the most common CABED. These findings may indicate the significance of continuing to implement group therapy and holding self-help groups under this pandemic, while considering social distance to prevent the spread of infection. This study also suggests that people with drug addictions should be wary when adapting to new 'self-restraint' and 'stay home' lifestyles during a pandemic, how to deal with alcohol, the socially accepted substance, and how to reconcile their ADHD, which may be a vulnerable factor for such lifestyle.

This study was conducted in MAP users who had access to a psychiatric hospital. Therefore, there are limitations regarding whether our findings can be generalized to all MAP users. Another limitation is that all study information, including whether the relapse was COVID-19-related, was determined solely by each participating hospital's attending psychiatrist. Moreover, the economic impact of the special fixedamount benefits (such unexpected income may ironically fund the purchase of MAP promoting relapse), and whether online group therapy and self-help groups are as effective as in-person gatherings were not considered.

Despite these limitations, this is the only Japanese study to date to investigate the impact of COVID-19 on MAP users; therefore this study not only has clinical implications, but is also important with regard to public health.

Collision of the COVID-19 and addiction epidemics

COVID-19 and addiction

The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment

COVID-19 stress and substance use: Current issues and future preparations

An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19

When epidemics collide: Coronavirus disease 2019 (COVID-19) and the opioid crisis

This study was supported by a Health Labour Research Grant from the Ministry of Health, Labour and Welfare, Research on Pharmaceutical and Medical Regulatory Science (Principal Investigator, Shimane T).

We declare that all authors have no interest of conflicts.